NICE recommends new treatment option for osteoporosis after menopause

The National Institute for Health and Care Excellence has recommended abaloparatide as a new treatment option for people with osteoporosis after menopause who are at a very high risk of fracture.1In final guidance, published 7 August, NICE said abaloparatide is a treatment for women who have not responded to or cannot use previously approved treatments. The drug is supplied in a prefilled pen so can be self-administered by patients at home.NICE said over 14 000 women in England could benefit from the drug which “increases bone density by stimulating the cells that make new bone and this reduces the risk of fracture.” It will be made available for use on the NHS in England within three months.Currently, patients with osteoporosis after menopause who are at very high risk of fracture are offered treatments such as romosozumab or teriparatide, followed by bisphosphonates.According to the NICE guidance, clinical trial evidence shows that…
Read Original Article: NICE recommends new treatment option for osteoporosis after menopause »